Rising PSA following treatment for malignant neoplasm of prostate
ICD-10 R97.21 is a billable code used to indicate a diagnosis of rising psa following treatment for malignant neoplasm of prostate.
Rising PSA (Prostate-Specific Antigen) levels following treatment for malignant neoplasm of the prostate indicate a potential recurrence of prostate cancer or treatment failure. PSA is a protein produced by both normal and malignant cells of the prostate gland, and its levels are monitored post-treatment to assess the effectiveness of interventions such as surgery, radiation, or hormone therapy. A rising PSA level can be a critical sign that warrants further investigation, including imaging studies or biopsy, to determine the presence of residual or recurrent disease. Clinicians must consider the patient's treatment history, the timing of PSA tests, and any accompanying symptoms such as urinary changes or bone pain. It is essential to differentiate between biochemical recurrence and other causes of elevated PSA, such as benign prostatic hyperplasia (BPH) or prostatitis, to guide appropriate management.
Documentation must include the patient's treatment history, PSA levels over time, and any symptoms or findings that may indicate recurrence.
Patients presenting for routine follow-up after prostate cancer treatment with elevated PSA levels.
Consideration of comorbid conditions that may affect PSA levels, such as BPH or urinary tract infections.
Acute care documentation should include the patient's presenting symptoms, PSA levels, and any immediate interventions performed.
Patients presenting with acute urinary retention or severe pain with a known history of prostate cancer and rising PSA.
Rapid assessment of potential complications related to prostate cancer recurrence, such as bone metastases.
Used to monitor PSA levels in patients with a history of prostate cancer.
Document the reason for the PSA test and the patient's treatment history.
Urology and oncology specialties may have specific protocols for PSA monitoring.
A rising PSA level following treatment for prostate cancer may indicate a recurrence of the disease or treatment failure, necessitating further evaluation.
